Alexza Pharmaceuticals Inc. raised $22 million in a public offering of stock and warrants.
Ceptaris Therapeutics Inc. secured $15 million in venture debt.
Collegium Pharmaceutical Inc. closed a $22.5 million Series B round.
InVivo Therapeutics Holdings Corp. raised $20 million through a public stock offering.
Satori Pharmaceuticals Inc. raised $15 million in an inside venture round.
Vascular Magnetics Inc. raised $7 million in Series A funding for magnetically targeted drug delivery.
Actelion Pharmaceuticals Ltd. licensed some ex-U.S. Xiaflex rights from Auxilium Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc. licensed EDP-239 to Novartis AG in a deal worth up to $440 million.
Retrophin LLC acquired a dual angiotensin/endothelin antagonist from Ligand Pharmaceuticals Inc.
Xencor Inc. and Boehringer Ingelheim GmbH will collaborate on biosuperior monoclonal antibodies.
. . . And More
Check BioWorld Today for coverage of the American Association for the Advancement of Science annual meeting.
Amsterdam Molecular Therapeutics Holding NV may be taken private by Forbion Capital Partners.
Chelsea Therapeutics International Ltd.'s Northera (droxidopa) got an FDA advisory panel's support.
Corcept Therapeutics Inc. won FDA approval of Korlym (mifepristone) for Cushing's syndrome.
Forest Laboratories Inc.'s inhaled aclidinium bromide got an advisory panel's backing in chronic obstructive pulmonary disease.
Gilead Sciences Inc. got disappointing Phase II HCV data with nucleotide polymerase inhibitor GS-7977.
GTx Inc.'s Phase II trials of prostate cancer drug Capesaris (GTx-758) were put on hold.
Threshold Pharmaceuticals Inc. saw its shares jump 88 percent on good Phase IIb data for TH-302.
Vivus Inc.'s obesity drug Qnexa (phentermine/topiramate) got a 20-to-2 backing from an advisory panel.